Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride Patent Expiration
Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride is Used for relieving symptoms of seasonal and perennial allergic rhinitis. It was first introduced by Kenvue Brands Llc
Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride Patents
Given below is the list of patents protecting Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zyrtec-d 12 Hour | US7014867 | Tablet comprising cetirizine and pseudoephedrine |
Jun 10, 2022
(Expired) | Kenvue Brands |
| Zyrtec-d 12 Hour | US7226614 | Tablet comprising cetirizine and pseudoephedrine |
Jun 10, 2022
(Expired) | Kenvue Brands |
| Zyrtec-d 12 Hour | US6469009 | Pharmaceutical compositions for the treatment of rhinitis |
Jul 13, 2019
(Expired) | Kenvue Brands |
| Zyrtec-d 12 Hour | US6489329 | Pharmaceutical compositions for the treatment of rhinitis |
Apr 08, 2016
(Expired) | Kenvue Brands |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride's patents.
Latest Legal Activities on Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Nov, 2018 | US7226614 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Sep, 2017 | US7014867(Litigated) |
| Recordation of Patent Grant Mailed Critical
| 05 Jun, 2007 | US7226614 |
| Patent Issue Date Used in PTA Calculation Critical
| 05 Jun, 2007 | US7226614 |
| Issue Notification Mailed Critical
| 16 May, 2007 | US7226614 |
| Dispatch to FDC | 07 May, 2007 | US7226614 |
| Application Is Considered Ready for Issue Critical
| 01 May, 2007 | US7226614 |
| Issue Fee Payment Received Critical
| 25 Apr, 2007 | US7226614 |
| Issue Fee Payment Verified Critical
| 25 Apr, 2007 | US7226614 |
| Mail Notice of Allowance Critical
| 06 Apr, 2007 | US7226614 |
Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride's Family Patents
